文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

高单不饱和脂肪酸低碳水化合物配方对重症神经科患者血糖及腹泻的治疗效果

[Therapeutic effects of high monounsaturated fatty acid and low carbohydrate formula on blood glucose levels and diarrhea in critically ill neurological patients].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2024-01-01
一句话结论高单不饱和脂肪酸低碳水化合物配方(Glucerna肠内营养制剂)可降低重症神经科患者血糖波动、高血糖发生率及每日胰岛素剂量,并改善腹泻症状。

该研究采用自身前后对照设计,纳入2023年11月至12月中山大学附属第一医院神经ICU的13例重症神经科患者,其中9例有高血糖史、8例有腹泻症状。使用高单不饱和脂肪酸低碳水化合物配方(Glucerna肠内营养制剂)后,血糖标准差、平均血糖、血糖中位数、血糖波动幅度、最大血糖波动幅度、血糖变异系数、高血糖发生率、严重高血糖发生率及每日胰岛素剂量均低于干预前,其中每日胰岛素剂量显著降低(P<0.05)。总蛋白、白蛋白、血红蛋白、C反应蛋白及白细胞计数干预前后无显著变化。腹泻症状改善时间为(3.50±1.41)天,干预后第7天Hart腹泻评分及第3、7天Bristol粪便分类评分均显著低于干预前(均P<0.05),失禁性皮炎分类亦改善。

要点

  • 13例重症神经科患者使用Glucerna肠内营养制剂后,每日胰岛素剂量显著降低(P<0.05),血糖标准差、平均血糖、血糖中位数、血糖波动幅度、最大血糖波动幅度、血糖变异系数、高血糖发生率及严重高血糖发生率均低于干预前。
  • 干预后第7天Hart腹泻评分(4.88±3.48 vs. 10.00±3.38)及第3、7天Bristol粪便分类评分(5.87±0.35、5.50±0.53 vs. 6.50±0.53)显著低于干预前(均P<0.05)。
  • 腹泻症状改善时间为(3.50±1.41)天;失禁性皮炎干预前以2级为主(71.43%),干预后第7天以1级为主(57.14%)。
  • 总蛋白、白蛋白、血红蛋白、C反应蛋白及白细胞计数干预前后无显著变化。

适用人群与场景

  • 2023年11月至12月中山大学附属第一医院神经ICU收治的13例重症神经科患者,其中9例有高血糖史、8例有腹泻症状。

诊断标准与关键阈值

  • 高血糖定义为血糖>7.8 mmol/L,严重高血糖定义为血糖>13.9 mmol/L。

处置流程与药物剂量

  • 使用高单不饱和脂肪酸低碳水化合物配方(Glucerna肠内营养制剂)进行肠内营养,干预前后7天内分析血糖指标变化。

研究设计与关键结果

  • 自身前后对照研究,纳入13例重症神经科患者,使用Glucerna肠内营养制剂后血糖标准差(mmol/L)1.83±1.11 vs. 2.10±1.13,平均血糖(mmol/L)8.87±2.03 vs. 9.75±1.37,血糖中位数(mmol/L)9.12±1.67 vs. 10.17±0.48,血糖波动幅度(mmol/L)0.66±0.31 vs. 0.78±0.32,最大血糖波动幅度(mmol/L)4.95±3.64 vs. 5.58±3.10,血糖变异系数16.00%(11.00%,28.50%)vs. 18.00%(12.50%,27.50%),高血糖发生率47.31% vs. 74.66%,严重高血糖发生率6.08% vs. 6.71%,每日胰岛素剂量(U)5.25(0.00,32.59)vs. 20.76(0.00,66.88),每日胰岛素剂量显著降低(P<0.05)。
  • 总蛋白、白蛋白、血红蛋白、C反应蛋白及白细胞计数干预前后无显著变化。
  • 腹泻症状改善时间(3.50±1.41)天,干预后第7天Hart腹泻评分(4.88±3.48 vs. 10.00±3.38)及第3、7天Bristol粪便分类评分(5.87±0.35、5.50±0.53 vs. 6.50±0.53)显著低于干预前(均P<0.05);失禁性皮炎干预前以2级为主(71.43%),干预后第7天以1级为主(57.14%)。

证据类型、等级与局限

  • 自身前后对照研究,样本量13例,原文未报告局限性。

对床旁实践的改变

  • 作者认为高单不饱和脂肪酸低碳水化合物配方对重症神经科患者的血糖控制和腹泻治疗有积极作用。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To investigate the effects of using a high monounsaturated fatty acid (MUFA) and low carbohydrate formula on blood glucose levels and diarrhea treatment effects in critically ill neurological patients.

METHODS: A self-controlled before-and-after study design was employed, with 13 patients admitted to the neurology intensive care unit (ICU) of the First Affiliated Hospital of Sun Yat-sen University from November to December 2023, who were treated with a high MUFA and low carbohydrate formula [Glucerna enteral nutrition (EN) preparation]. Changes in blood glucose parameters within 7 days before and after the use of Glucerna EN preparation were analyzed, including standard deviation (SD) of blood glucose, mean blood glucose (MG), median blood glucose, mean amplitude of glycemic excursions (MAGE), largest amplitude of glycemic excursions (LAGE), coefficient of variation (CV) of blood glucose, the incidence of hyperglycemia (> 7.8 mmol/L) and severe hyperglycemia (> 13.9 mmol/L), and daily insulin dose. Changes in total protein (TP), albumin (ALB), hemoglobin (Hb), C-reactive protein (CRP), and white blood cell count (WBC) were observed before and after intervention. Improvement in diarrhea symptoms, Hart diarrhea score, Bristol Stool classification score, and incontinence dermatitis classification were also analyzed before and after the use of Glucerna EN preparation.

RESULTS: A total of 13 critically ill neurological patients were enrolled, among whom 9 patients had a history of hyperglycemia and 8 patients had diarrhea symptoms. After intervention with Glucerna, the patients' SD of blood glucose, MG, median blood glucose, MAGE, LAGE, CV of blood glucose, incidence of hyperglycemia, incidence of severe hyperglycemia, and daily insulin dose were all lower than those before the intervention [SD of blood glucose (mmol/L): 1.83±1.11 vs. 2.10±1.13, MG (mmol/L): 8.87±2.03 vs. 9.75±1.37, median blood glucose (mmol/L): 9.12±1.67 vs. 10.17±0.48, MAGE (mmol/L): 0.66±0.31 vs. 0.78±0.32, LAGE (mmol/L): 4.95±3.64 vs. 5.58±3.10, CV of blood glucose: 16.00% (11.00%, 28.50%) vs. 18.00% (12.50%, 27.50%), hyperglycemia incidence: 47.31% vs. 74.66%, severe hyperglycemia incidence: 6.08% vs. 6.71%, daily insulin dose (U): 5.25 (0.00, 32.59) vs. 20.76 (0.00, 66.88)], with a significant decrease in daily insulin dose after the intervention (P < 0.05); TP, ALB, Hb, CRP and WBC showed no significant changes before and after the intervention with Glucerna EN preparation. The improvement time of diarrhea symptoms after intervention was (3.50±1.41) days, and the Hart diarrhea score on the seventh day after intervention (4.88±3.48 vs. 10.00±3.38) and the Bristol Stool classification score on the third and seventh days after intervention (5.87±0.35, 5.50±0.53 vs. 6.50±0.53) were significantly lower than before the intervention (all P < 0.05). Before the intervention with Glucerna EN preparation, the classification of incontinence dermatitis was mainly classified as Grade 2 severity (71.43%); after the intervention, it significantly improved by the seventh day, with Grade 1 being the main classification (57.14%).

CONCLUSIONS: The high MUFA and low carbohydrate formula has a positive effect on blood glucose control and diarrhea treatment in critically ill neurological patients.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Huang X, Lai R, Yang Q, et al. [Therapeutic effects of high monounsaturated fatty acid and low carbohydrate formula on blood glucose levels and diarrhea in critically ill neurological patients]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2024. PMID: 39380521. doi:10.3760/cma.j.cn121430-20240123-00078

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。